Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
MD-76R is a radiographic contrast agent containing diatrizoate meglumine and diatrizoate sodium administered by injection for diagnostic imaging procedures. It enhances visualization of internal body structures during radiological examinations by increasing radiodensity in target tissues. This is a legacy small-molecule contrast medium used primarily in conventional radiology and fluoroscopy.
As a 35-year-old legacy contrast agent approaching loss of exclusivity with moderate competitive pressure (30%), the commercial team is likely focused on managed decline and operational efficiency rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
MD-76R presents limited career growth opportunity given zero linked job openings and mature LOE-approaching status; roles available focus on efficiency, cost control, and market maintenance rather than expansion. Working on this product develops expertise in managed decline strategies and operational excellence within a shrinking product category.
Worked on MD-76R at Guerbet? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.